Entries |
Document | Title | Date |
20080207763 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic - A composition and method of treating fever, and optionally treating pain, is disclosed. The composition and method utilize a nonopioid analgesic and an endothelin antagonist as active agents to treat fever in mammals, including humans. The composition also is useful in the prevention and treatment of stroke and other cardiovascular disorders, like myocardial infarction. | 08-28-2008 |
20080269344 | Beta2-Adrenergic Receptor Agonists - Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor. | 10-30-2008 |
20080293821 | Cooling compositions - Disclosed are improved cooling compositions comprised of N-(2-hydroxyethyl)-2,3-dimethyl-2-isopropylbutyramide and at least one other cooling agent. The cooling compositions may be used alone or in products such as a chewing gum or a confection. | 11-27-2008 |
20090093548 | COLCHINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 04-09-2009 |
20090143474 | REDUCED DOSE INTRAVENOUS ACETAMINOPHEN - Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever. | 06-04-2009 |
20090170955 | Fast Release Paracetamol Tablets - A pharmaceutical composition such as a swallow tablet or capsule formulation is described comprising paracetamol, calcium carbonate, at least one binding agent and at least one disintegrating agent in the form of a granulate, optionally combined with one or more pharmaceutically acceptable extragranular components. | 07-02-2009 |
20090176886 | Polymorphic Forms of Oseltamivir Phosphate - The present invention relates to polymorphic forms of (3R,4R,5S)-5-amino-4-acetylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acid ethyl ester phosphate, which is a potent inhibitor of viral neuraminidase. | 07-09-2009 |
20090215903 | Injectable Liquid Paracetamol Formulation - The invention relates to an aqueous paracetamol solution for administration by means of infusion with a pH of between 4.5 and 6, containing at least one substance that can react with fenolates to produce the O-derivatives thereofor other co-ordination compounds. The injectable paracetamol solution has high stability, does not become coloured over time and has a minimum impurity content. | 08-27-2009 |
20090215904 | COLCHICINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 08-27-2009 |
20090312433 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT - The present invention relates to a method of reducing a VR1-antagonist-induced increase in body temperature in a mammal in need thereof, comprising the step of administering an antipyretic agent to the mammal and the like. | 12-17-2009 |
20100063157 | CHEMICAL PROCESS AND NEW CRYSTALLINE FORM - The present invention relates to the preparation of a β | 03-11-2010 |
20100069501 | Pharmaceutical Composition Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and Paracetamol - A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) Paracetamol or a derivative thereof; a pharmaceutical composition and/or dosage form comprising such a combination as well as a method of treating one or more of pain and ostheoarthritis in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to said mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 03-18-2010 |
20100152298 | Present invention relates to a treatment for the management of cancer more specially the use of Flutamide anti-androgen drugsa - This invention helps in the treatment and the management of cancer. It is the use of flutamide drug to treat and manage cancer where the Flutamide anti-androgen drug acts in another mechanism other than the well know androgen respects (AR) mechanism. | 06-17-2010 |
20100234472 | NITRIC OXIDE RELEASING DERIVATIVES OF PARACETAMOL - The present invention particularly relates to novel nitrate esters of paracetamol. The nitrate esters of paracetamol are prepared by reacting the paracetamol with dihaloalkyl compound and followed by reaction with silver nitrate to obtain the corresponding nitrate ester derivatives. The nitrate esters of paracetamol are useful as analgesic, anti-inflammatory agents. | 09-16-2010 |
20100240761 | BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS - Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided. | 09-23-2010 |
20110015273 | STABLE PHARMACEUTICAL AQUEOUS COMPOSITIONS - The present invention refers to an parenterally administerable aqueous formulation containing paracetamol. For enhancing stability the formulation contains a sulphur containing antioxidant, preferably sodium metabisulfite. For making the formulation more soluble it contains hydroxy propyl beta cyclodextrin. The composition is used as analgesic. | 01-20-2011 |
20110039938 | STORAGE-STABLE FORMULATION OF PARACETAMOL IN AQUEOUS SOLUTION - The present invention concerns a liquid formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent obtainable by the following steps: (i) dissolving in a reaction vessel paracetamol in an aqueous solvent having a temperature between 65° C. and 95° C., and having pH between 5.0 and 6.0; (ii) cooling the solution so formed to a temperature equal to or above 35° C. and below 40° C. under an atmosphere of nitrogen; (iii) adding cysteine hydrochloride and sodium hydroxide simultaneously to the solution without stirring; (iv) closing the reaction vessel, and stirring the solution of step iii) in a nitrogen atmosphere. It further relates to a method for preparing the formulation. | 02-17-2011 |
20110039939 | STORAGE-STABLE FORMULATION OF PARACETAMOL IN AQUEOUS SOLUTION - The present invention concerns a liquid formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent obtainable by the following steps: (i) dissolving in a reaction vessel paracetamol in an aqueous solvent having a temperature between 65° C. and 95° C., and having pH between 5.0 and 6.0; (ii) cooling the solution so formed to a temperature equal to or above 35° C. and below 40° C. under an atmosphere of nitrogen; (iii) adding cysteine hydrochloride and sodium hydroxide simultaneously to the solution without stirring; (iv) closing the reaction vessel, and stirring the solution of step iii) in a nitrogen atmosphere. It further relates to a method for preparing the formulation. | 02-17-2011 |
20110046227 | METHODS FOR CONCOMITANT ADMINISTRATION OF COLCHICINE AND A SECOND ACTIVE AGENT - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., atorvastatin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 02-24-2011 |
20110046228 | METHODS FOR ADMINISTRATION OF COLCHICINE WITH GRAPEFRUIT JUICE - Methods for safe administration of colchicine together with consumption of grapefruit juice are disclosed. | 02-24-2011 |
20110046229 | Controlled Release Drug Delivery Systems And Pharmaceutical Compositions Formed Therewith - The present invention relates to controlled release drug delivery systems. In one embodiment, the present invention relates to controlled release drug delivery systems comprising a combination of at least one polyacrylic acid and at least one enteric polymer. In another embodiment, the present invention relates to a controlled release pharmaceutical composition comprising the combination of at least one active pharmaceutical ingredient and a controlled release drug delivery system, where the controlled release drug delivery system comprises the combination of at least one polyacrylic acid and at least one enteric polymer. | 02-24-2011 |
20110178180 | DEUTERIUM-ENRICHED COLCHICINE, THIOCOLCHICINE, AND DERIVATIVES THEREOF; METHODS OF PREPARATION; AND USE THEREOF - Disclosed herein are deuterium-enriched colchicine, thiocolchicine, and derivatives thereof. The deuterium-enriched compounds are useful as, an antiproliferative agent, a muscle relaxant, an anti-inflammatory agent, or an anti-gout agent. | 07-21-2011 |
20110190396 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 08-04-2011 |
20110190397 | Methods for Concomitant Administration of Colchicine and a Second Active Agent - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 08-04-2011 |
20110207824 | FORMULATION OF AN INJECTABLE PARACETAMOL SOLUTION, METHOD FOR PREPARING AND PACKAGING SUCH A SOLUTION AND DEVICE FOR PACKAGING SUCH A SOLUTION - A simplified paracetamol solution for an injectable and ready-to-use preparation is only composed of paracetamol, bi-distilled water and a buffer agent, the formulation having a maximal paracetamol concentration of 1 g/100 ml, a pH between 5.5 and 6.5 and an oxygen content inferior to 0.2 ppm. A method for preparing and packaging such a solution and a device for packaging such a solution are also disclosed. | 08-25-2011 |
20110207825 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 08-25-2011 |
20110213037 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 09-01-2011 |
20110263716 | COLCHINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 10-27-2011 |
20110275720 | METHODS FOR CONCOMITANT ADMINISTRATION OF COLCHICINE AND A SECOND ACTIVE AGENT - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 11-10-2011 |
20120016036 | MATERIAL AND METHODS FOR TREATING DEVELOPMENTAL DISORDERS INCLUDING COMORBID AND IDIOPATHIC AUTISM - Subjects who were diagnosed with either comorbid or idiopathic autism were treated with acamprosate. Patients generally showed marked improvements in primary outcomes as assessed using, for example, standard clinic measures for functionality including the Clinical Global Impressions Improvement (CGI-I) and the Clinical Global Impressions Severity (CGI-S) scales. | 01-19-2012 |
20120108667 | HYDROXY CERAMIDES AND ANALOGS THEREOF AND THEIR USE FOR PREVENTING OR TREATING CANCER - Disclosed herein are compounds, compositions, methods of treatment and synthetic methods for making compounds related to Ceramides and the use of Ceramides. | 05-03-2012 |
20120115958 | LIQUID PHARMACEUTICAL FORMULATION CONTAINING PARACETAMOL - The present invention relates to a sugar-free liquid pharmaceutical formulation comprising an aqueous solution of paracetamol, a solubilizing agent containing polyethylene glycol, a thickening agent containing xanthan gum, and a sweetening system containing sucralose and a mixture of polyols containing glycerol, sorbitol and xylitol in a total amount between approx. 15% and 35% w/v relative to the total volume of said pharmaceutical formulation. | 05-10-2012 |
20120178819 | Selective, Lipophilic, and Long-Acting Beta Agonist Monotherapeutic Formulations and Methods for the Cosmetic Treatment of Adiposity and Contour Bulging - Provided herein are pharmaceutical and cosmetic formulations and methods for regional adiposity reduction and treatment of body contour defects such as abdominal bulging; comprising an injectable formulation, said formulation comprising: an active ingredient that consists essentially of an adipose tissue-reducing amount of one or more lipophilic long-acting selective beta-2 adrenergic receptor agonists, or salts, solvates, or polymorphs thereof; and one or more subcutaneously acceptable inactive ingredients. | 07-12-2012 |
20120184623 | AMIDE DERIVATIVES OF VALPROIC ACID AND USES THEREOF - Amide derivatives of valproic acid are provided along their use in the treatment of epilepsy. | 07-19-2012 |
20120190750 | STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION - The invention concerns a stable aqueous paracetamol solution for use in IV infusion comprising at least one stabilizing-dissolving compound for paracetamol in solution selected from the group consisting of hydroxyalkyl-cyclodextrins and at least one stabilizing compound, being EDTA or monothioglycerol, alone or in combination, in a concentration between 0.001% and 20% m/v. | 07-26-2012 |
20120245230 | METHOD AND COMPOSITION FOR PREPARING STABLE LIQUID FORMULATIONS OF PARACETAMOL - The present invention relates to stable liquid formulations of paracetamol for pharmaceutical use and to a method of preparation of stable paracetamol solutions. | 09-27-2012 |
20130079416 | HOMEOPATHIC MEDICAMENT COMPRISING PHENACETIN FOR THE TREATMENT OF CANCER - The present invention relates to a composition comprising phenacetin, in particular a Phenacetinum 4CH homeopathic medicament for use in the treatment of cancer. | 03-28-2013 |
20130096201 | Pharmaceutical Compositions Comprising Paracetamol and Process for Preparing The Same - Disclosed herein are injectable compositions containing high concentration of paracetamol or its pharmaceutically acceptable salts wherein the concentration of paracetamol or its pharmaceutically acceptable salt is >150 mg/ml in a judiciously tailored solvent system comprising glycofurol, ethanol, water or a solvent system comprising glycofurol, ethanol, polyethylene glycol, water. The viscosity of the said injectables is <28 cps. Further disclosed is the process for preparing the said injectables. The injectables can be administered by intramuscular route, intravenous route or as intravenous infusion after diluting in one of the routinely used intravenous fluids, infusion solutions of antibacterial, antifungal and amoebicidal drugs and along with anxiolytics (Midazolam injection) or narcotic analgesics (Fentanyl Citrate injection etc) as they remain stable, clear and transparent at least for 6 hours after dilution. | 04-18-2013 |
20130109757 | PROCESS FOR THE PREPARATION OF PYRROLINES FROM GAMMA-NITROKETONES. USE OF THE GAMMA-NITROKETONES AS PESTICIDAL AGENTS | 05-02-2013 |
20130116330 | COLCHICINE SOLID-STATE FORMS; METHODS OF MAKING; AND METHODS OF USE THEREOF - Disclosed are new colchicine solid-state forms, methods of preparing the solid-state forms, as well as formulations prepared therefrom and uses thereof. | 05-09-2013 |
20130178535 | Acetaminophen Composition - The present invention describes a liquid injectable composition comprising acetaminophen, hydroxyethylstarch and at least one osmolality agent. Further, the invention relates to a pharmaceutical composition for the prophylaxis and treatment of pain and fever containing said injectable composition. Additionally, the invention relates to a process for the manufacturing of the composition as well as a container comprising said liquid injectable composition. | 07-11-2013 |
20130210922 | STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION - The invention concerns a stable aqueous paracetamol solution for use in IV infusion comprising at least one stabilizing-dissolving compound for paracetamol in solution selected from the group consisting of cyclodextrins, at least one stabilizing compound bearing at least one thiol functional group and at least one stabilizing compound selected from the group consisting of Thiamine salts. | 08-15-2013 |
20130303621 | Method For Inhibiting Osteoclast Development - This invention provides a composition comprising Formula I, or salt thereof, | 11-14-2013 |
20140005272 | ADMINISTRATION OF N,N-DIMETHYLACETAMIDE AND ITS MONOMETHYLATED METABOLITES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | 01-02-2014 |
20140057986 | GENE AND GENE EXPRESSED PROTEIN TARGETS DEPICTING BIOMARKER PATTERNS AND SIGNATURE SETS BY TUMOR TYPE - Provided herein are methods and systems for identifying a therapeutic for an individual, such as a therapeutic not previously identified for treating the individual. The therapeutic can be identified by molecular profiling, such as determining the biomarker patterns or signature sets of a biological sample of an individual. | 02-27-2014 |
20140066516 | Novel Method - The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent. | 03-06-2014 |
20140107213 | METHODS FOR ADMINISTRATION OF COLCHICINE WITH GRAPEFRUIT JUICE - Methods for safe administration of colchicine together with consumption of grapefruit juice are disclosed. | 04-17-2014 |
20140179795 | Agent for Stabilizing Acetaminophen - Provided is an agent for stabilizing acetaminophen in an aqueous composition, the agent comprising glycine. The agent further comprising at least one kind of sulfurous acid salt selected from the group consisting of sodium sulfite, potassium sulfite and potassium pyrosulfite is more effective. The stabilizing includes preventing precipitation. | 06-26-2014 |
20140221494 | MEDICAMENT - A medicament for treating upper respiratory mucosal congestion, the medicament having a combination of:
| 08-07-2014 |
20140243416 | Topical Antiandrogen Therapy for the Treatment of Becker's Nevus - This invention relates to the treatment of Beckers nevus with antiandrogenic topical agents, including 5-alpha reductase inhibitors, non-steroidal antiandrongens and steroidal antiandrogens. | 08-28-2014 |
20140303254 | Process Of Manufacturing A Stable, Ready To Use Infusion Bag For An Oxidation Sensitive Formulation - A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient is provided. The oxidation susceptible active pharmaceutical ingredient is mixed with excipients and deoxygenated water to prepare a non-sterile drug solution. The non-sterile drug solution is filled into a moist heat sterilizable flexible infusion bag. The flexible infusion bag with the non-sterile drug solution is terminally moist heat sterilized at a preset air overpressure between about 0.2 bar to about 1.2 bar to obtain a parenteral drug product. The highest degradation product in the parenteral drug product is less than 0.5% by weight of a labeled amount of the oxidation susceptible active pharmaceutical ingredient in the parenteral drug product. | 10-09-2014 |
20140309309 | COSMETIC FORMULATION - The invention relates to a cosmetic formulation and to its use. | 10-16-2014 |
20150038588 | COMPOSITIONS AND METHODS OF TREATMENT OF STATUS EPILEPTICUS - The invention provides a method of treating benzodiazepine-resistant status epilepticus in a subject having been exposed to a nerve agent inducing the status epilepticus. | 02-05-2015 |
20150057358 | NOVEL SUSTAINED RELEASE DOSAGE FORMS - A sustained release dosage form comprises an active ingredient blended with a polymeric matrix. At least a portion of the polymeric matrix is formed by a cellulose ether having an onset dissolution temperature of at least 40° C., having anhydroglucose units joined by 1-4 linkages and having methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituents such that the cellulose ether has an MS (hydroxyalkyl) of 0.05 to 1.00, and hydroxyl groups of anhydrogluclose units are substituted with methyl groups such that [s23/s26−0.2*MS(hydroxyalkyl)] is 0.31 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group. | 02-26-2015 |
20150057359 | METHODS OF COLCHICINE ADMINISTRATION - The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug. | 02-26-2015 |
20150087715 | POLYMORPHIC FORM OF A LONG-ACTING BETA-2 ADRENOCEPTOR AGONIST - New polymorphic form of a long-acting beta-2 adrenoceptor agonist A new polymorphic form of arformoterol tartrate, designated as form D, is provided and which is characterised by at least one of the following: (i) a powder X-ray diffraction pattern having peaks at approximately 6.8, 13.3, 13.6, 3.8, 14.1, 18.2, 18.7, 20.0±0.2 degrees two theta; or (ii) a DSC thermogram showing an endothermic peak with an onset at approximately 19-120° C., and a maximum at approximately 129-131° C., followed by an exothermic peak with a maximum at approximately 137-138° C.; wherein the DSC thermogram of form D has a further endothermic peak with an onset at approximately 168-170° C.1 Processes for preparing the new polymorphic form, uses thereof and intermediates for the preparation thereof, are also provided. | 03-26-2015 |
20150094375 | METHODS OF COLCHICINE ADMINISTRATION - The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug. | 04-02-2015 |
20150119468 | PROTECTION FROM CHEMICAL-INDUCED ACUTE LUNG INJURY - Methods are provided herein for treating an individual having a disease, disorder or condition affecting the lungs, wherein said disease, disorder, or condition of the lung is an acute lung injury. In specific embodiments, the acute lung injury is chemical induced acute lung injury (CIALI). In some embodiments, the methods are provided for treating or protecting a subject from chemical induced acute lung injury that include administering to the subject a therapeutically effective amount of a phosphatase located on chromosome 10 (PTEN) inhibitor such as N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl)pivalamide (SF1670). In some embodiments, the method products a subject from CAILI or reduces CAILI that results from a subsequent exposure to a chemical that induces chemical induced acute lung injury. | 04-30-2015 |
20150141518 | WATER-MISCIBLE STABLE SOLUTION COMPOSITION FOR PHARMACEUTICALLY ACTIVE INGREDIENTS THAT ARE POORLY SOLUBLE IN WATER AND SUSCEPTIBLE TO CHEMICAL DEGRADATION - A method to improve the stability of unstable drug substances in solution is described. Such solution compositions are water -miscible, can be refrigerated, sterilized and even co-administered with other pharmaceutical products without causing precipitation of the active ingredient. A particular example of such a stable, water-miscible solution composition for paracetamol is disclosed. | 05-21-2015 |
20150352214 | FUNCTIONAL STARCH POWDER - Functional starch powder of 400% or more water retention capacity, 5 hr or more collapse time and 200 g or more gel indentation load. | 12-10-2015 |
20160000925 | Preparations, Methods And Kits Useful For The Treatment Of Cough - The invention relates to a respiratory preparation providing cough relief in a human comprising: a film forming agent; a thickening agent; and the respiratory preparation provides on demand relief. Additionally, the invention relates to a method of providing cough relief in a human comprising: the steps of administering to a human a respiratory preparation comprising: a film forming agent; a thickening agent; and wherein said respiratory preparation provides on demand cough relief as needed. | 01-07-2016 |
20160089341 | METHODS FOR TREATING AND PREVENTING STATUS EPILEPTICUS AND ORGANOPHOSPHATE POISONING - Disclosed are compounds, compositions and methods for stopping seizures, including status epilepticus, and are useful for the treatment and prevention of seizure disorders. | 03-31-2016 |
20160114047 | COMPOSITION FOR APPLICATION TO A MUCOSA COMPRISING A METHYLCELLULOSE - A composition designed for application to a mucosa comprises a tonicity-adjusting agent, a methylcellulose, and a liquid diluent, wherein the methylcellulose has anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.36 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups. | 04-28-2016 |
20160128952 | Pharmaceutical Combination - A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) Paracetamol or a derivative thereof, a pharmaceutical formulation and a dosage form comprising said combination as well as a method of treating pain, e.g. chronic or acute pain, characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 05-12-2016 |
20160144033 | CONCENTRATED ACETAMINOPHEN SOLUTION - A concentrated acetaminophen solution is provided that is dissolved in polyethylene glycol (PEG) with trace water. The acetaminophen is present in the PEG at a concentration of at least 200 mg per mL. The composition is useful to deliver or safely store concentrated doses of acetaminophen without degradation of the acetaminophen. | 05-26-2016 |
20160145198 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions. | 05-26-2016 |
20160158171 | METHOD FOR TREATING INFLAMMATION AND PAIN - The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ω-(methylsulfonyl)alkylamine or ω-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ω-(methylsulfonyl)alkylamine or ω-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. | 06-09-2016 |
20160199325 | INJECTABLE LIQUID PARACETAMOL FORMULATION | 07-14-2016 |